ASPirin for Acute Pneumonia in the elderlY (ASPAPY): protocol of a multicentre randomised double-blind placebo-controlled trial.

Date publication

mai 2025

Journal

BMJ open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FOURNEL Isabelle

Tous les auteurs :
Putot A, Manckoundia P, Ksiazek E, Cortier M, Cransac A, Fournel I,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40341146

Résumé

Acute pneumonia (AP) remains a leading cause of death in the older population. Excess risk of death after AP is partly due to cardiovascular (CV) events. We aim to evaluate whether aspirin at a preventive dose (100 mg daily) introduced at the acute phase of AP reduces 90-day mortality.

Mots clés

Aged, Cardiovascular Disease, Mortality, Randomized Controlled Trial, Respiratory infections

Référence

BMJ Open. 2025 05 7;15(5):e102768